Mannatech results
This article was originally published in The Tan Sheet
Executive Summary
Firm's net sales increase 7.6% to $58.4 mil., with earnings up 118.8% to $3.1 mil. in the first quarter (ended March 31). Mannatech attributes the results to "building momentum" from new and existing associates and members. The firm's sales associates brought 141,000 new customers in the 12 months ended March 31, according to CEO Samuel Caster. Mannatech plans to launch products in South Korea in the third quarter and roll out Ambrotose AO in the United Kingdom, Japan, Australia and New Zealand later this year...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.